Program LKI Symposium “Tumor Immunology & Immunotherapy: harnessing the immune system to fight cancer” Leuven, Campus Gasthuisberg, Onderwijs en Navorsing II 12-14 September 2016
Day 1 12:30 - 13:30 13:30 - 13:40
Registration and coffee Welcome and opening by Prof. Dr. Wim Robberecht, Vice-rector of KU Leuven and Chairman of the Board University Hospitals Leuven Prof. Dr. Jo Van Lint, Coordinator for Translational Cancer Research of the Leuven Cancer Institute
Session 1: Defining tumor antigens and immunogenicity (Chair: Prof. Karim Vermaelen, University of Ghent) Prof. Dr. Pierre Coulie (UCL, Woluwe) “Tumor heterogeneity: a problem for cancer immunotherapy” 13:40 -- 14:20 Poster blitz sessions (20 posters, 2-min each)(posters nr 1-20, see list on page 3-5 below) 14:20 - 15:00 Prof Dr. Zlatko Trajanoski (Biocenter, Innsbruck) “Pan-cancer immunogenomic analyses reveal 15:00 - 15:40 genotype-immunophenotype relationships and predictors of response to checkpoint blockade” 15:40 - 16:00 REFRESHMENTS Session 2: Vaccine based immunotherapy (Chair: Prof. Viggo Van Tendeloo, University of Antwerp) 16:00 - 16:40 Prof. Dr. Carl Figdor (Radboud University Medical Center, Nijmegen, NL) “Dendritic cell based immunotherapy” Selected oral communication 16:40 - 17:00 17:00 - 17:40 Prof. Dr. Zwi Berneman (University of Antwerp) “Dendritic cell vaccines for leukemia” 17:40 - 17:50 Concluding remarks day 1 19.00 – 22.00
Dinner (speakers)
Day 2 08:00 - 08:50 08:30 - 08:50 08:50 - 09:00
"Meet the expert" breakfast with Prof. Carl Figdor, Prof. Zlatko Trajanoski, and Prof. Zwi Berneman Arrival Welcome
Session 3: Immunotherapy hurdles and how to overcome them (Chair: Prof Zwi Berneman, University of Antwerp) 09:00 - 09:40 Prof. Dr. Karim Vermaelen (University of Ghent) “The “Jekyll and Hyde” of the tumor-associated dendritic cell system in lung cancer and its potential clinical relevance” 09:40 - 10:20 Poster blitz sessions (20 posters, 2-min each) (posters nr 21-41, see list on page 3-5 below) 10:20 - 11:00 Prof. Dr. Aurelien Marabelle (Institut Gustave Roussy, Paris) “How can we overcome resistance to immune checkpoint blockade?” 11:00 - 11:20 REFRESHMENTS
Session 4: Tumor targeting antibodies (Chair: Prof. Patrick Neven, KU Leuven) 11:20 - 12:00 12:00 - 12:20 12:20 - 13:00 13:00 - 14:00 13:00 - 14:00
Dr. Jeroen Lammerts van Bueren (CEO of Genmab, Utercht, NL) “Antibodies for the treatment of hematological malignancies” Selected oral communication Prof. Dr. Özlem Türeci (Ganymed, Mainz) “Developing immune effector mobilizing antibodies in nonhematological cancers" LUNCH - poster viewing – meet the expert lunch "Meet the expert” lunch with Prof. Pierre Coulie, Dr Jeroen Lammerts van Bueren, Prof. Karim Vermaelen and Prof. Aurelien Marabelle
Session 5: Adoptive T-cell therapy (Chair: Prof. Dr. Steven Devleeschouwer, KU Leuven) 14:00 - 14:40 Prof. Dr. Viggo Van Tendeloo (University of Antwerp) “The Ins and outs of generating redirected T cells using T cell receptor gene transfer for cancer immunotherapy” Selected oral communication 14:40 - 15:00 15:00 - 15:40 Prof. Dr. Reno Debets (Erasmus University, Rotterdam, NL) “T Cell Receptor-Engineered T Cells to Treat Solid Tumors” 15:40 - 16:00 REFRESHMENTS Session 6: Gut microbiota, immunity and cancer (Chair: Prof. Geert Van Loo, IRC, VIB-Gent) 16:00 - 16:40 Dr. Maria Paula Roberti (Institut Gustave Roussy, Paris) “Gut microbiota and cancer therapeutics” 16:40 - 17:00 Selected oral communication 17:00 - 17:20 Best poster awards and concluding remarks day 2
19:00 - 22:00
Dinner (conference) Day 3
08:00 - 08:50 08:30 - 08:50 08:50 - 09:00
"Meet the expert" breakfast with Prof. François Ghiringhelli and Prof. Len Seymour Arrival Welcome
Session 7: Inflammation, tumor microenvironment and immune escape (Chair: Prof. Dr. Patrizia Agostinis, KU Leuven) 09:00 - 09:40 Prof. Dr. Massimilano Mazzone (VIB and Vesalius Research Center, KU Leuven) “Influence of Macrophage Metabolism on Vessel Shape” 09:40 - 10:00 Selected oral communication Prof. Dr. François Ghiringhelli (INSERM, Dijon) “Chemotherapy and anticancer immune responses" 10:00 - 10:40 10:40 - 11:00 REFRESHMENTS Session 8: New approaches to cancer immunotherapy (Chair: Prof. Bart Vandekerckhove, University of Ghent) 11:00 - 11:40 Dr. Abhishek Garg (KU Leuven) “Cancer cell death "with a twist": Towards next-generation dendritic cell immunotherapy” 11:40 - 12:00 Selected oral communication 12:00 - 12:40 Prof. Dr. Len Seymour (University of Oxford, UK) “Targeting immunotherapy to tumours using oncolytic viruses” 12:40 - 13:00 Concluding remarks 13:00 - 14:00 LUNCH - poster viewing – meet the expert lunch 13:00 - 14:00 "Meet the expert” lunch with Prof. Reno Debets, Dr. Maria Paula Roberti, Prof. Max Mazzone, Prof. Viggo Van Tendeloo and Dr. Abhishek Garg
List of poster abstracts (listed alphabetically by family name of presenting author) Please mount your poster on the board corresponding to your poster number in the poster hall at floor 6. Posters 1-‐20 will be presented in 2 minute blitz slide sessions on 12 September from 14:20-‐15:00 Posters 21-‐41 will be presented in 2 minute blitz slide sessions on 13 September from 09:40-‐10:20 1 2
3
4
5
6
7 8
9
10
11 12
13
14
Ana Rita Antunes1,2, Karen De Vlaminck1,2, Jo Van Ginderachter1,2*, Kiavash Movahedi1,2* ASSABBAN Assiya1, Andrianne Mathieu1, Blackshear Perry J.2, Van Maele Laurye1, Goriely Stanislas1 Bala Attili1, Petya Georgieva2, Dieter Ory1, Thomas Mathivet2, Joost Dejaegher3, Steven De Vleeschouwer3, Guy Bormans1 Baert T1,2, Garg AD3, Vindevogel E2, Van Hoylandt A1,2, Verbist G4, Agonistinis P3, Vergote I1,2, Coosemans A1,2 Baert T1,2, Mathivet T3, Van Hoylandt A1,2, Vergote I1,2, Coosemans A1,2 Jochen Belmans(1), Matthias Van Woensel(2,3), Brecht Creyns(4), Jean-‐Pierre Locquet(5), Dominique Bullens(1,6), Stefaan Van Gool(1,7) Mohammed Benkheil, Sam Noppen, Jan Paeshuyse, Johan Neyts, Sandra Liekens Bonelli Stefano1,2, Laoui Damya 1,2, Keirsse Jiri 1,2 , Schoonooghe Steve 1,2, Van Ginderachter Jo1,2 Diana Campillo-‐Davo1, Fumihiro Fujiki2, Johan Van den Bergh1, Evelien Smits1,3,4, Haruo Sugiyama2, Viggo F.I. Van Tendeloo1, Zwi Berneman1,3, Flora D’Anna§1,2, Hui Zhao§1,2, Rebecca V. Berrens3,4, Liesbeth Minnoye1,2, Savvas N. Savvides5,6, Wolf Reik3,7,8,9, Bernard Thienpont#1,2, Diether Lambrechts#1,2 Lutz Nuhn,a Sunil A. David,b Stefaan De Kker,c and Bruno G. De Geest Yannick De Vlaeminck1, Cleo Goyvaerts1, Carlo Heirman1, Kris Thielemans1, Jo Van Ginderachter2,3 and Karine Breckpot1 Joost Dejaegher, MD (1) – Ellen Vercalsteren (1) – Louis Boon, PhD (2) – Steven De Vleeschouwer, MD, PhD (1) Isabelle Dierckx de Casterlé1, Omer Rutgeerts1, Sabien Fevery1, Stefaan Van Gool2, Mark Waer1, An D. Billiau1, Ben Sprangers1,3
15
Monica Gordon-‐Alonso, Claude Wildmann, Thibault Hirsch and Pierre van der Bruggen
16
Chunyan Gu-‐Trantien1$, Edoardo Migliori1, Laurence Buisseret1,2, Alexandre de Wind3,
Dissecting the heterogeneity and functions of tumor-‐ associated macrophages in glioblastoma Tristetraprolin expression by keratinocytes plays a key role in the control of inflammation and carcinogenesis. In Vitro Positron emission tomography imaging of Translocator protein (TSPO) in brain tumors In vitro generation of murine dendritic cells for cancer immunotherapy: An optimized protocol Tumor-‐associated macrophage phenotype makes low grade ovarian cancer a possible target for immunotherapy Immunotherapy with subcutaneous autologous tumor lysate increases glioblastoma survival in temozolomide treated mice Hepatitis C Virus induced EGFR activation: role in liver pathogenesis Targeting Neuropilin-‐1 through single-‐domain antibodies: a novel strategy to tackle tumor-‐ associated macrophages Electroporation of Dicer-‐substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms’ tumor 1 (WT1)-‐specific TCR-‐ redirected cytotoxic T Cells Hypoxia, DNA methylation and retrotransposons: an opportunity for cancer immunotherapy?
Biomimetic nanoparticles for lymph node focused immune activation Dissecting the biology of tumor-‐associated macrophages using lentiviral vectors and nanobodies PD-‐1 expression and therapeutic blockade in the GL261 murine malignant glioma model. Immunotherapy for high-‐risk neuroblastoma: allogeneic stem cell transplantation and recipient leucocyte infusion. Tumor microenvironment restrains cytokine diffusion: a novel mechanism for tumor immune evasion Tfhx13 cells link immune suppression and adaptive memory in human breast cancer
17
18
19
20
21
22
23
24
25
26
27
Sylvain Brohée2, Soizic Garaud1, Luan Dang4, Jean-‐Nicolas Lodewyckx1, Céline Naveaux1, Hugues Duvillier5, Stanislas Goriely6, Denis Larsimont3 and Karen Willard-‐Gallo1 Marc Hennequart1,2, Luc Pilotte1,2, Stefania Cane1,2, Vincent Stroobant1,2, Etienne De Plaen1,2, Benoit Van den Eynde1,2,3;*. Jacobs Julie1,2, Deschoolmeester Vanessa1,2, Zwaenepoel Karen1, Hermans Christophe1,2, Rolfo Christian3,4, Lardon Filip1, Siozopoulou Vasiliki2, Smits Evelien1,5, Pauwels Patrick1,2 Eva Van Overmeire1,2,*, Evangelia Bolli1,2,*, Mate Kiss1,2, Andrea Casazza3, , Jiri Keirsse1,2, Imane Song4, Isabelle Houbracken4, Inge Vercauteren1,2, Yvon Elkrim1,2, Frank Tacke5, Louis Boon6, Massimiliano Mazzone3, Sofie Struyf7, Damya Laoui1,2,$ and Jo A. Van Ginderachter1,2,$ Klaessens S1, De Plaen E1, Stroobant V1 and Van den Eynde B1. S.K. Larsen1, D. Schröder1 (MD), J. Carrasco2,3 (MD, PhD) , O. Bricard1, G. Hames1, N. Remy1, Missault Kevin1, J.-‐L. Canon2,3 (MD), P Vannuffel4 (PhD), C. Galant5 (MD, PhD), M. Berlière5 (MD, PhD), P. G. Coulie1 (MD, PhD). Heleen Dewittea, Sandra Van Lintb, Katrien Vanderperrenc, Emmelie Stockc Stefaan C. De Smedta, Karine Breckpotb and Ine Lentackera Stéphanie Liénart1†, Julia Cuende1†, Olivier Dedobbeleer1, Bas van der Woning2, Gitte De Boeck2, Julie Stockis1, Caroline Huygens1, Didier Colau3, Joan Somja4, Philippe Delvenne4, Muriel Hannon4, Frédéric Baron4, Laure Dumoutier3, Jean-‐Christophe Renauld3, Hans De Haard2, Michael Saunders2, Pierre G. Coulie1 and Sophie Lucas1 Alessandra Lopes1, Kevin Vanvarenberg1, Véronique Préat1 and Gaëlle Vandermeulen1. Ken Maes1, Sarah Melhaoui1,2, Brenda De Keersmaecker2, Karine Breckpot2, Kim De Veirman1, Eline Menu1, Elke De Bruyne1 and Karin Vanderkerken1 Elly Marcq1, Vasiliki Siozopoulou1,2, Jorrit De Waele1, Jonas Van Audenaerde1, Karen Zwaenepoel1,2, Eva Santermans3, Niel Hens3,4, Patrick Pauwels1,2, Jan P van Meerbeeck1,5p, Evelien LJ Smits1,6p B. Mertens, TC. Nogueira, D. Topalis, R. Stranska, G. Andrei, R. Snoeck Rega Institute for medical research, KU Leuven, Leuven Belgium
Cyclooxygenase-‐2 triggers constitutive tryptophan catabolism in human tumors and favors immune evasion CD70-‐positive colorectal cancer associated fibroblasts: prognostic factor and immune escape mechanism The CCL8/CCR8 axis maintains an immunosuppressive tumor microenvironment
Characterization of a feedback loop that regulates the activity of TDO, an enzyme involved in tumor immune escape. Determining the frequency and clonality of known tumor-‐specific cytolytic T cells in the blood of a patient with primary breast carcinoma Microbubbles as magic bullets in cancer immunotherapy Monoclonal antibodies against GARP/TGF-‐ 1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Optimization of DNA cancer vaccine increases antigen production and delays P815 mastocytoma tumor growth Decitabine and quisinostat exert immunogenic effects in the 5T33 murine multiple myeloma model. Characterization of the tumor microenvironment and investigation of immune checkpoint expression in malignant pleural mesothelioma Addition of an adjuvant to cidofovir treatment of primary human papillomavirus positive tumor influences untreated secondary tumor in mice
28
29
30
31
32
33
34
35 36
37
38
39
40
41
Vladan Milosevic, Joanna Kopecka, Iris C. Salaroglio, Silvia Novello, Luisella Righi, Giorgio Scagliotti, Chiara Riganti Erminia Romano1, Abhishek D Garg1, Hannelore Maes1, Aleksandra Dudek-‐Peric1, Hannelie Korf2, Peter De Witte3 and Patrizia Agostinis1# Nicole Rufo1, Abhishek D. Garg1, Thomas Sauter2, Jean-‐Christophe Marine3, Patrizia Agostinis1 P. Ruytinx1, N. Berghmans1, N. Pörtner1, L. Vanbrabant1, S. Noppen2, S. Liekens2, I. Ronsse1, J. Van Damme1, S. Struyf1 Marco BE Schaaf1, Hannelore Maes1, Sampad Jana2, Joice Thomas2, Kasper MA Rouschop3, Wim Dehaen2, Patrizia Agostinis1 Karolin Schneider1, Vanesa Bol1, Pierre Coulie2, Vincent Grégoire1
Ariane Scoumanne1, Virginie Rabolli1*, Murielle Martini1*, Marie-‐Claire Letellier1, Stefano Crosignani1, Christophe Quéva1, Michel Detheux1, Jakub M Swiercz1*, Sandra Cauwenberghs1* Trompet Erika1, Tousseyn Thomas2, Snoeck Robert1, Andrei Graciela1 Heleen H. Van Acker,1 Ottavio Beretta,2 Sébastien Anguille,1,3 Lien De Caluwé,1,4 Angela Papagna,2 Johan M. Van den Bergh,1 Yannick Willemen,1 Herman Goossens,1 Zwi N. Berneman,1,3 Viggo F. Van Tendeloo,1 Evelien L. Smits,1,3,5 Maria Foti,2 Eva Lion1,3 Van den Bergh JMJ*1, Willemen Y1, Lion E1, De Reu H1, Berneman ZN1, Van Tendeloo VFI1, Smits ELJM1,2 Damya Laoui1,2,*, Jiri Keirsse1,2,*, Yannick Morias1,2, Patrick De Baetselier1,2, Massimiliano Mazzone5,6, Martin Guilliams3,4,$, Jo A. Van Ginderachter1,2,$ Van Hoeck J.1, Wayteck L.1, Dewitte H.1, Xiong R.1, Breckpot K.2, Braeckmans K.1,3, De Smedt S.C.1, Raemdonck K.1 Matthias Van Woensel (1,2) & Thomas Mathivet (3,4), Nathalie Wauthoz (2), Rémi Rosière (2), Véronique Mathieu (5), Robert Kiss (5), Florence Lefranc (6), Louis Boon (7), Jochen Belmans (8), Stefaan W. Van Gool (9), Holger Gerhardt (3,4), Karim Amighi (2), Steven De Vleeschouwer (1,10) Mathias Wenes1,2, Min Shang1,2, Mario Di Matteo1,2, Jermaine Goveia3,4, Rosa Martín-‐ Pérez1,2, Jens Serneels1,2, Hans Prenen5, Bart Ghesquière6,7, Peter Carmeliet3,4, Massimiliano Mazzone1,2
Malignant pleural mesothelioma creates an immunosuppressive microenvironment due to the presence of cancer stem cells BNIP3: a key modulator of the melanoma-‐ macrophages interface Systems Biology of Immunogenic Cell Death (ICD) in Melanoma Angiostatic activity of two natural CXCL4L1 isoforms Derivatives of chloroquine to improve anticancer therapy Radiation induced immunogenic cell death signals in human HPV-‐positive and HPV-‐negative HNSCC cell lines Development and validation of a phenotypic screening platform for the identification of novel immuno-‐oncology targets Organotypic epithelial raft cultures for the ex vivo study of lymphoproliferative disorders Superior cytolytic immune effector cell recruitment by interleukin-‐15 dendritic cells
Transpresentation of interleukin-‐15 by IL-‐15/IL-‐15R mRNA-‐engineered human dendritic cells boosts antitumoral natural killer cell activity The tumor microenvironment harbors ontogenically distinct dendritic cell populations with opposing effects on tumor immunity Hitchhiking nanoparticles: exploring novel siRNA delivery approaches on cytotoxic T cells Sensitization of glioblastoma tumor micro-‐ environment to chemo-‐ and immunotherapy by Galectin-‐1 intranasal knock-‐down strategy
Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis
For more information, please contact:
Prof. Dr Jo Van Lint Leuven Cancer Institute (LKI)
[email protected] More info: kuleuvencongres.be/leuvenimmuno2016/
